Shares of Glen mark Parma surged 3.3
percent intraday Tuesday on receiving USFDA sanction for skin treatment by its
US additional. "Glen mark Generics Inc, USA, the subsidiary of Glen mark
Generics, has been settled final approval from the United States Food and Drug management
(US FDA) for its condensed new drug application (ANDA) for Fluocinonide Cream
USP 0.1 percent, the broad version of Vanes Cream by Medicos," says the
company in its filing.
Fluocinonide Cream is indicated for
the relief of the inflammatory and cleanliness manifestations of corticosteroid
responsive dermatomes. "VANOS unguent is a instruction corticosteroid
(steroid hormone) used on the skin (topical) to treat adults and children 12
years of age and older with confident skin conditions that cause red, flaky,
and itchy skin," says Medicis. According to IMS Health sales data for the
12 month stage finish March 2014, Fluocinonide Cream garnered yearly sales of
approximately USD 103 million. Glenmark’s current portfolio consists of 93
products authorised for allotment in the US marketplace and 71 ANDA’s pending
approval with the US FDA. "In adding up to these internal filings,
Glenmark Generics Inc continues to identify and explore external development
partnerships to supplement and speed up the growth of the accessible pipeline
and selection," it adds. At 10:36 hours IST, the stock was quoting at Rs
551.75, up 2.34 percent on the BSE.
No comments:
Post a Comment